We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Abbott Laboratories | NYSE:ABT | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.35 | -1.26% | 105.92 | 106.92 | 105.895 | 106.92 | 5,073,972 | 00:37:24 |
From May 2019 to May 2024
By Chris Wack
Abbott Laboratories (ABT) has received approval from the Food and Drug Administration for a next-generation version of its leading MitraClip heart valve repair device used to repair a leaky mitral valve without open-heart surgery.
The Abbott Park, Ill.-based company said in a release Thursday that it received CE Mark for the next-generation device earlier this year, allowing for sale of the devices in the European Union and other countries that recognize the regulatory designation.
The next-generation MitraClip system provides cardiologists with advanced steering, navigation and positioning capabilities for the clip, making it easier to use in difficult anatomies, Abbott said.
Abbott recently began enrollment in the MitraClip EXPAND clinical study, a prospective study evaluating the safety and performance of the new MitraClip system in a contemporary real-world setting.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 12, 2018 09:37 ET (13:37 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Abbott Laboratories Chart |
1 Month Abbott Laboratories Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
